Every question patent owners ask. Answered with data.

Choose one of four commercialization paths — license it, sell it, build on it, or partner around it — and start pursuing it deliberately. Research on US inventors found only about 55% of strong patents are ever commercialized; the rest sit idle, not for lack of value, but for lack of a decision.

An unused patent has three honest options: monetize it (license or sell), hold it strategically, or let it go and stop paying fees. Large-scale inventor surveys across the US, Europe, and Japan confirm that a substantial share of patents are 'sleeping' — never used internally or licensed — so you're in the majority, and the majority is leaving money on the table.

Four routes: license it for royalties, sell it outright, build a product or company on it, or partner (joint ventures, strategic alliances). The global IP licensing market alone was valued at roughly $340 billion in 2024 — the money is real, but it flows to owners who deliberately pursue one of these paths.

Yes — patents are transferable property, and outright sales happen every day. The tracked brokered secondary market moved roughly $158 million in 2024, in line with the prior two years, through a stable community of brokers and buyers.

Probably less than you hope and more than zero — patent values are extremely skewed. A major European study found a mean patent value above €3 million, a median about one-tenth of that, and a most-common value of only a few thousand euros. A small tail of patents carries almost all the value.

Identify companies whose products overlap your claims, build a short evidence-backed pitch, and approach their licensing or business-development contact directly. Deals typically take one of two shapes: about 41% of licenses use a running royalty on sales, while 34% are structured as lump-sum payments.

Selling transfers ownership permanently for a one-time price; licensing keeps ownership with you and grants usage rights in exchange for royalties or fees. Non-exclusive licensing is the single largest deal type — about 42% of the patent licensing market — because owners can license the same patent to multiple companies at once.

Economic research suggests the size of the innovation should drive the choice: smaller innovations tend to suit outright sales, while moderate-to-large innovations often earn more through royalty-bearing licenses. Your capital position and desired involvement matter just as much.

Look at who cites your patent, who holds adjacent patents, and whose products overlap your claims — those are your warmest targets. And consider this: brokers and professional intermediaries are involved in 87% of successfully sold patent packages, because finding the real buyer is the hardest part.

Lead with evidence of use — a clear picture of where your patent reads on products already selling. Brokered-market data shows evidence-of-use materials are the clearest path to both a higher price and a higher likelihood of closing. Everything else is supporting detail.

No — a granted patent, clear claims, and a credible market story open licensing conversations every day. Only about 40% of patented inventions ever reach market launch or mass production, which means most interest and most deals happen well before a finished product exists.

Yes — that's exactly what licensing exists for. Enterprises, not inventors, account for roughly 54% of the patent licensing market as end users; the entire market is built around owners who license out rather than build.

Months to years, depending on the path: an outright sale can close in a few months with a motivated buyer, licensing commonly takes six months to two years of outreach and negotiation, and building a product or company is measured in years. Brokered-market data shows patent packages routinely sell even after three-plus years on the market — patience is normal.

The folk statistic says under 10%; rigorous survey work paints a more nuanced picture — about 55% of high-quality (triadic) patents are commercialized in some form, while over half of all US patents are abandoned early for unpaid maintenance fees. Quality and owner effort swing the number enormously.

Usually it's packaging or pricing, not the invention. Brokered-market analysts describe the current market as one where sellers struggle while buyers 'quietly clean up' — prices have stabilized below seller expectations, and evidence-light listings get ignored while well-packaged ones move.

Professionally, through cost, market, and income approaches — but here's the humbling part: a landmark study found that citations, claims, references, and family size combined explain only about 2.7% of the variance in patent value. Real valuation is mostly judgment about markets, which is why structured expert scoring exists.

Five factors dominate: market size, claim breadth and strength, remaining patent life, detectability of infringement, and industry momentum. Renewal data backs this up — patents their owners pay to keep alive have measurably more claims, more prior-art citations, more forward citations, and longer prosecution histories than abandoned ones.

Buyers pay for patents that read on revenue: claims covering products already selling or clearly coming. Empirical work confirms it — litigated and highly cited patents are measurably more valuable, because both signals indicate the patent touches something the market actually cares about.

There's no honest average — and brokers famously call average price-per-patent 'the worst thing that ever happened to patents.' The brokered market moved about $158 million in 2024 across tracked packages, with individual sales ranging from five figures for single assets to millions for strong portfolios with evidence of use.

Across the Licensing Executives Society's 2021 high-tech survey, the average royalty rate was 4.82% of sales and the median 4.75%; combining four surveys since 2011, the average is 5.66% with a 5% median. Two-thirds of all royalty rates land at 5% or less, and 90% at 10% or less.

Through a risk lens: validity, infringement evidence, design-around difficulty, and strategic fit. Notably, the 2021 LES survey found only 24% of licensors entered deals for purely monetary reasons — down from 54% in 2014 — while future collaboration rose to 36%. Buyers increasingly evaluate the relationship, not just the asset.

Ask the market's own test: would someone pay to keep this alive? Renewal research shows 53.7% of all patentees eventually decide no and let their patents lapse — and the survivors share identifiable traits: more claims, more citations, longer prosecution. Strength is measurable, not mysterious.

Yes — that's exactly what the Beyond the Patent Commercialization Score does. And the case for structured scoring is empirical: even the best bibliometric indicators (citations, claims, family size, geography) explain only about 11% of patent-value variation. The other 89% requires multi-factor human analysis — which is what a score formalizes.

Benchmark against two public datasets: citation and claim profiles in the patent record, and royalty benchmarks in your industry. Thirty years of deal data show industry medians ranging from 4.3% (semiconductors) to 6.1% (medical/health, telecom) — knowing your industry's band tells you whether your expectations match your market.

Both extremes carry risk — narrow patents are easy to design around, broad ones are easier to challenge — but data offers a floor test: patents that owners pay to maintain have significantly more claims than abandoned ones. Claim count and claim independence are among the few reliable, measurable value signals.

Directly — remaining term defines how many years of royalty income or exclusivity a buyer is purchasing. Academic value studies deliberately analyze full-term patent cohorts because expiring patents lose their tail value almost entirely; practitioners discount steeply once fewer than about five years remain.

The market dominates. Research on patent value found that even claims, citations, references, and filing geography together leave about 89% of value variation unexplained — the difference is context: whether a real market exists, whether it's growing, and whether money is flowing into the space.

Yes — and the data says you should. Research estimates the rents patents capture at only about 2% of R&D spend, meaning owners systematically overestimate what their patent should be worth based on what they invested. An independent read is cheap insurance against both overpricing and underselling.

Three groups: operating companies protecting or expanding product lines, investment firms and aggregators building IP portfolios, and occasionally competitors who'd rather own your patent than design around it. Market reports note operating companies remain active sellers and buyers — and that NPEs (licensing enforcement firms) purchase a growing share of brokered packages.

Yes, though the deck is tilted: research on US patent values found patents held by small patentees are systematically less valuable than those held by large corporations — largely because imperfect technology markets make it harder for individuals to reach and negotiate with buyers, not because the inventions are worse.

Aggregators and NPEs buy patents to license or enforce them rather than to build products. They're legitimate, well-funded buyers — NPEs purchase a growing share of brokered deals — but market data shows packages they pick up are among the most litigated assets on earth, which is a trade-off to price in, not a reason to refuse.

Brokers package your patent, run a confidential sale process to their buyer network, and negotiate the deal — typically for a success fee of 20–35% of the sale price. Their dominance is empirical: brokers are involved in about 87% of sold packages in the tracked secondary market.

Brokers dominate the visible market, but private direct deals are rising — analysts note the shift is partly why the public brokered market has shrunk by several metrics. Direct sales keep the full price and the relationship; brokered sales bring reach and process. The right choice depends on whether you already know your buyer.

Through the right door — licensing teams, business development, or formal open-innovation portals — with evidence, not enthusiasm. North America holds roughly 40% of the global IP licensing market, concentrated in companies like IBM, Qualcomm, and Microsoft that run professional inbound IP processes.

Broker networks, online marketplaces, and direct outreach are the three real channels. The scale is bigger than most owners realize: market trackers follow more than 19,000 patent packages covering over 340,000 individual assets — visibility is solved; standing out is the challenge.

Sometimes — but set expectations with the data: the entire tracked brokered market cleared about $158 million in 2024 against hundreds of thousands of listed assets. Marketplaces work for well-packaged patents in active technology areas; they function as graveyards for undocumented listings.

Structure it around evidence of use — market analysis consistently identifies it as the clearest driver of both sale price and likelihood. One page showing whose products your claims read on beats ten pages describing how clever the invention is.

Your granted patent is the protection — that's what it's for. The more relevant data point: over half of all patents are abandoned for unpaid maintenance fees, which means the statistically bigger risk for most owners isn't theft, it's an unpitched, unpolished, or unfunded patent quietly expiring.

It's the contract that permanently transfers patent ownership from seller to buyer — the legal engine of the roughly $158-million-a-year brokered sale market. Recording the assignment with the USPTO makes the transfer part of the public record.

Often more favorably than owners expect: qualifying individual inventors can frequently treat patent sale proceeds as long-term capital gains under IRC Section 1235 rather than ordinary income — a potential difference of roughly 20 percentage points depending on your bracket. Structure matters enough to justify professional tax advice before you sign.

Exclusive gives one company sole rights (usually for higher royalties or upfront payments); non-exclusive lets you license the same patent to multiple companies. Non-exclusive is actually the market's largest segment — about 42% of patent licensing deals — because most markets have more than one credible player.

The essentials: licensed patents and scope, exclusivity, royalty structure and rate, minimum royalties, milestones, audit rights, term and termination, improvement rights, and infringement responsibilities. Universities alone reported nearly 2,000 license amendments in 2025 — what goes into the original agreement decides how much pain comes later.

Both, usually. The 2021 LES survey found 41% of deals use a running royalty on sales and 34% use lump-sum payments, with much of the remainder blending the two — an upfront payment to cover your costs and commit the licensee, plus royalties for the upside.

Minimum royalties are guaranteed annual payments regardless of sales; milestones are payments triggered by events like regulatory approval or first commercial sale. They matter because the dominant structure is percentage-of-sales — 93% of royalty deals — which pays you nothing if the licensee never actually sells anything.

Licensing the same patent for one application area while reserving others — for example, licensing your materials patent for automotive use while keeping medical and consumer rights for yourself or other licensees. LES survey methodology tracks field of use as a standard deal dimension because rates vary measurably by field.

Yes — that's non-exclusive licensing, and it's the largest deal type in the market at roughly 42%. Economic research even shows that licensors of significant innovations rationally license to multiple competing firms, because a market of licensees pays more than one.

Most licenses run either a fixed multi-year term or the life of the patent — and the calendar matters: US utility patents run 20 years from filing, with maintenance-fee cliffs at 3.5, 7.5, and 11.5 years. Smart terms map renewal and renegotiation points to those dates.

Sometimes — sublicensing lets your licensee license others, which can dramatically expand distribution, but it dilutes your control and typically your rate. It's common enough that sub-licensing is its own recognized segment of the licensing market alongside exclusive and non-exclusive deals.

Without protective clauses: nothing — they hold your rights and owe you little. The base rate justifies the paranoia: only about 40% of patented inventions reach market launch even when commercialization is genuinely attempted. Minimum royalties, performance milestones, and reversion clauses exist precisely for this scenario.

Both are standard practice, and geography genuinely changes your buyer: Asia Pacific leads the patent licensing market with about 36% revenue share while North America leads broader IP licensing at roughly 40%. Where your patent family is filed decides which levers you actually have.

Anchor at the data, not the anecdotes: 65% of all royalty rates are 5% or less, and 90% are 10% or less. A first-time licensor with a solid patent should expect to negotiate in the low single digits — and remember that 3% of a big market beats 10% of a small one.

Your license's audit clause lets an accountant inspect the licensee's books to verify royalty reports — typically once a year, sometimes with a 'true-up' trigger when underpayment exceeds a threshold. It's not paranoid, it's standard: the royalty benchmarks everyone relies on are themselves sourced from SEC filings, because even public numbers need checking.

No — individuals license and sell patents in their own name all the time, and 45% of licensees in the 2021 LES survey had annual sales under $25 million, meaning small entities are mainstream counterparties, not exceptions. A company becomes useful when you're building, raising money, or want liability separation.

The proven paths: licensing advances, strategic partners, grants, and IP-anchored equity. The scale is encouraging — universities alone generated $3.6 billion in license income in a single year while spinning out 1,095 startups, showing how routinely IP anchors real funding.

Yes — it happens systematically, not just occasionally. University licensing data shows licenses with startups grew 15% and agreements including equity grew 16% in 2025: investors routinely take equity positions anchored on IP before a product exists.

Real but specialized — IP-backed lending and securitization are named growth trends in IP market analyses. The honest caveat: lenders typically want portfolios with proven licensing revenue or litigation-grade evidence, not a single untested patent, and terms reflect how hard patents are to liquidate.

Bottom-up beats top-down: count the products your claims could read on, their prices, and their volumes, then sum. Context helps — IT & telecom alone represents about 38.5% of the patent licensing market, so which slice you're sizing matters as much as the total.

Wildly path-dependent — which is the point. Getting the patent itself typically runs $10,000–$20,000+ all-in through grant; commercializing adds anywhere from near-zero (a pure licensing campaign) to seven figures (building a product company). Choosing the path is choosing the budget.

The menu is wider than most owners know: option agreements (a company pays to evaluate exclusively for a period), equity-for-IP deals, joint ventures, sponsored development, and hybrids of all four. Options and equity are the growth segments — option agreements rose 10% and equity-included deals 16% in a single year.

A startup fits when the patent anchors a whole company — a platform, a new category, no adequate incumbent to license to. Licensing fits when existing players can reach the market better than you ever will. The base rates: roughly 7,000 operational startups exist solely to commercialize university IP — the path is proven, but it's the minority route.

Anchor on the market and comparable deals, not your costs — research estimates patent rents at only about 2% of R&D spend, meaning sunk development cost is a terrible predictor of value. Investors price the opportunity the IP protects, discounted for everything still unproven.

The carrying costs arrive on a schedule whether or not revenue does: USPTO maintenance fees at 3.5, 7.5, and 11.5 years, escalating at each stage — thousands of dollars in government fees alone before a dollar of royalty arrives. Add packaging, outreach, and legal costs, and a realistic pre-revenue budget has real teeth.

Map your claims against products already selling: read your independent claims element by element, then hunt for products that contain every element of at least one claim. This 'evidence of use' work isn't just for enforcement — brokered-market data calls it the clearest path to a higher price and a higher likelihood of sale.

If you're building and selling product, usually yes; if you're licensing or selling the patent itself, the question flips — your buyer runs FTO on their own plans. Context for the stakes: median litigation cost for a mid-size patent case runs about $1.7 million, which is why FTO opinions in the low five figures are considered cheap insurance.

Free public databases (Google Patents, USPTO, Espacenet) plus one insider move: the secondary market itself. Market trackers follow over 340,000 assets across 19,000+ sale packages — what's being sold, by whom, and at what asking price is a free competitive-intelligence feed most owners never think to read.

A structured map of every relevant patent in a technology area: who owns what, how claims relate, where the white space is, and who's citing whom. It's worth doing because citations carry real information — research found citations explain patent value as much as claims, references, and family size combined.

Often more than the one you invented it for — and the answer changes your royalty expectations, since industry medians run from 4.3% (semiconductors) to 6.1% (medical/health, telecom) across 15 tracked industries. Cross-industry applicability changes both your buyer list and your rate.

Start from concentration, not breadth: in recent tracked years, software alone accounted for 52% of brokered patent sales — buyers cluster by sector, so a focused list of 20–50 well-chosen targets outperforms a blast to hundreds.

Test it against money already moving: cross-border payments for licensed IP hit a record $1.32 trillion in 2025 — up from $728 billion in 2015, growing about 6% a year. Global demand for licensed technology is real and expanding; the question is whether your slice of it is.

Usually less than you fear. Research on patent strategy found 17% of patents are held at least partly for preemption — blocking competitors — but only 3% are purely preemptive. Overlapping patents typically signal a shared, validated market and a race to license, not a dead end.

Two educations at once: technical (expired patents are free to practice — a public-domain R&D library) and commercial (over half of all patents are abandoned for unpaid fees, so the graveyard shows you exactly what the market judged not worth carrying).

Through technology transfer offices (TTOs) that patent university inventions and license them to companies. The scale: in a single year, US institutions reported $104 billion in research expenditures, 25,000+ invention disclosures, roughly 3,000 patent licenses, $3.6 billion in license income, and 714 new commercial products.

Start with your technology transfer office — in most cases the institution owns the patent and the TTO runs the process. The momentum is with you: university startup creation surged 15% in a year to 1,095 companies, and academic licensors are now the majority in high-tech licensing surveys.

Usually the employer does, or at least holds rights — most employment agreements assign invention rights, and the patent's listed assignee in the public USPTO record usually answers the question in one lookup. If no assignment exists, inventorship and ownership are legally distinct, and that's attorney territory.

First, check the fee status — 53.7% of patents are abandoned at maintenance deadlines, and inherited patents lapse by default while estates settle. Then record the ownership transfer with the USPTO, and only then decide: maintain, monetize, or let go.

Plenty — orphaned and divested patents are a recognized, actively traded asset class in the roughly $158-million-a-year secondary market. The first step is title: confirm the chain from the defunct company to you is clean and recorded.

Carefully — under US law (35 U.S.C. §262), each joint owner can generally license the patent independently without the others' consent or a duty to share proceeds. That freedom makes buyers nervous and discounts the asset, which is why sorting co-ownership terms first usually pays for itself.

Country by country — patents are territorial, so monetization follows where you actually entered national phase. The prize justifies the effort: cross-border IP payments hit a record $1.32 trillion in 2025, with the US and Japan leading exports and Ireland and China leading imports.

Possibly. Patents that lapsed for unpaid maintenance fees can often be revived if the delay was unintentional — the USPTO even revised its delay-petition rules in August 2026. Truly expired (end-of-term) patents are done, but the technology and any live family members may not be.

Yes — and you should. Deals are routinely discussed during pendency and closed at grant, and research quantifies why: being refused a patent reduces the probability of reaching market launch by about 13 percentage points — a pending application already carries most of the commercial leverage.

Often yes — a live continuation keeps your options open to adjust claims as the market develops. The data agrees that families signal value: family size and related applications are among the few characteristics that reliably distinguish maintained, valuable patents from abandoned ones.

Usually not, but the comparison misses the point — they protect different things. Design patents cover appearance only and trade at a structural discount, but they cost a fraction of utility patents, issue faster, require zero maintenance fees, and in design-driven consumer markets can be the asset that matters.

Run the math honestly: fees arrive at 3.5, 7.5, and 11.5 years and escalate each time, and 53.7% of owners eventually answer this exact question by walking away. Keep paying if the patent is in an active deal pipeline or clearly reads on a live market; stop if it's had years of silence and no strategy.

When the data has voted: renewal research shows abandoned patents share identifiable traits — fewer claims, fewer citations, shorter prosecution — and market data shows even good packages can sit unsold for three-plus years. Weak traits plus years of genuine, well-packaged effort plus another fee cliff is the walk-away pattern.

More than owners budget: a single US utility patent typically costs $10,000–$20,000+ through grant, plus three escalating maintenance payments to reach year 20. Multiply across family members and foreign jurisdictions — each with their own annuities — and carrying a real family to term runs well into six figures.

Document first, contact second. Build an evidence-of-use file showing exactly how their product meets your claims — that file is simultaneously your licensing pitch and your litigation foundation. And know the stakes before escalating: the median mid-size patent case costs about $1.7 million through trial.

Rarely as the opening move. A C&D can trigger a declaratory-judgment lawsuit in the recipient's choice of court — handing them the home-field advantage — and it burns the licensing relationship before it starts. Most monetization professionals open with a licensing conversation and hold legal threats in reserve.

Sometimes — but the math is brutal. Even a 'small' patent case with under $1 million at stake carries a median cost around $800,000. Litigation monetizes only when the evidence of use is strong, the defendant has real revenue, and the patent survives scrutiny — a small fraction of situations.

By spreadsheet: expected license cost versus expected litigation cost versus design-around cost, all discounted by probability. One structural shift matters to you — the PTAB's inter partes review process helped drive median litigation costs down 47% in two years, because accused infringers can now challenge validity relatively cheaply.

US utility patents run 20 years from the earliest filing date — check yours in any patent database. And yes, remaining term changes everything: academic value studies focus on full-term patents because value concentrates there, and practitioners discount steeply once under about five years remain.

Build when the patent anchors a whole company — a platform or new category with no incumbent who could serve the market better. License when existing players already own the channels. Both paths are thriving: university IP startups surged 15% in a year while non-exclusive licensing remains the market's largest segment at about 42%.

Pitch the partnership, not just the patent — the data says it works: in the 2021 LES survey, 'future collaboration' overtook pure money as the leading licensor motive (36% vs 24%). Companies increasingly want ongoing relationships with the people behind the IP.

Yes — IP-anchored JVs are a standard structure: you contribute the patent (or a license to it), a partner contributes capital, manufacturing, or distribution, and the venture shares the outcome. Equity-for-IP structures are measurably growing — agreements including equity rose 16% in a single year of university licensing data.

Structured for change: the best partnerships define milestones, fields of use, and expansion rights from day one — because they will be amended. Universities alone reported nearly 2,000 license amendments in a single year; even the most professional counterparties renegotiate constantly.

For consumer products with a demonstrable prototype, yes — crowdfunding is a demand test and a funding round in one. Context: only about 40% of patented inventions ever reach market launch, so a patent plus a working demo already puts you ahead of most campaigns; IP alone, however, doesn't fund.

Through their technology transfer or sponsored-research offices — and they're motivated, high-volume counterparties: in a single year, US institutions executed roughly 3,000 patent licenses, 3,200+ copyright licenses, and 1,600+ other agreements. Standard templates make universities among the most predictable partners in IP.

More often than owners assume — and the buyers are active: aerospace and defense companies were the single largest group of licensees in the 2021 LES high-tech royalty survey. Dual-use technology (civilian and military applications) is a recognized and well-funded commercialization lane.

Turns an unpriced asset into a priced, packaged, pursue-able opportunity: assessing commercial potential, building the target list, preparing the evidence, and guiding the path. The case for help is empirical — brokers and professional intermediaries are involved in 87–90% of successfully sold patent packages. Owners who go professional close; owners who wing it mostly don't.

Quotes depend on scope — a single-patent score is a different engagement from portfolio strategy — so email ad@broadview-holdings.com with your patent number for a specific quote. For context on what guessing wrong costs: even a small patent lawsuit carries a median cost near $800,000, and owners collectively abandon 53.7% of patents after paying years of fees.

Beyond the Patent is an IP commercialization platform — a wholly-owned Broadview Holdings company — founded by Axel D'Addario, a strategist whose ventures have built $150M+ in enterprise value. The two brands form one progression: Beyond the Patent is where newly granted patents get scored and a path gets chosen; Broadview Holdings is where established organizations execute.